Ernexa Therapeutics (ERNA)
Nasdaq Market Closed
Ernexa Therapeutics Inc. is a preclinical biotechnology company focused on developing engineered allogeneic induced mesenchymal stem cell, or iMSC, therapies for cancer and other diseases with significant unmet medical need. The company’s work sits at the intersection of cell therapy, immuno-oncology, and synthetic biology, using stem-cell-derived platforms designed to deliver therapeutic payloads directly within diseased tissue.
Its lead program, ERNA-101, is being developed for oncology applications, with an initial focus on platinum-resistant ovarian cancer. The candidate is designed to use the natural tumor-homing characteristics associated with mesenchymal stem cells to reach the tumor microenvironment and release pro-inflammatory factors intended to help overcome local immune suppression. This approach aims to turn the tumor site into a more hostile environment for cancer cells while concentrating therapeutic activity where it is needed.
Ernexa is also pursuing ERNA-201, a program built around iMSCs that secrete the anti-inflammatory cytokine IL-10. That candidate is being explored for autoimmune and inflammatory disorders, including rheumatoid arthritis, where modulating immune activity may have therapeutic potential.
As a preclinical-stage company, Ernexa does not yet have approved commercial products and its business is centered on research, platform development, manufacturing strategy, and preparation for potential clinical testing. Its prospects depend on the successful advancement of its cell therapy candidates through preclinical validation, regulatory review, human trials, and eventual commercialization. The company operates as a specialized R&D organization within the broader biotechnology market.
Last updated
- Market Cap
- $7,067,978
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -$2,109,022
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141
No recent news is linked to this listing.
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $7,067,978
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -$2,109,022
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.03
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.21
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -9.78
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$7,255,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -166.25%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -108.16%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.89
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.89
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 2.65
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $49,207
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 6.06
Income Statement
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Revenue | — | 582K | 68K | — | — |
| Cost of revenue | 0 | 96K | 236K | 0 | 0 |
| Gross profit | — | 486K | -168K | — | — |
| Operating income | -9.32M | -15.67M | -21.14M | -33.22M | -113.73M |
| EBITDA | -9.06M | -14.04M | -20.59M | -26.73M | -113.62M |
| Net income | -14.1M | -44.56M | -21.68M | -24.6M | -122.56M |
| Income taxes | -45K | 30K | -3K | 45K | 64K |
| Interest expense | -27K | -6.75M | -614K | -30K | — |
| Other operating expenses | 0 | -1.58M | 460K | 5.99M | 5.77M |
| Total operating expenses | 9.32M | 16.16M | 20.97M | 33.22M | 113.73M |
| Basic EPS | -56 | -1,224 | -1,530 | -3,022.5 | -21,228.75 |
| Diluted EPS | -56 | -1,224 | -1,530 | -3,022.5 | -21,228.75 |
Balance Sheet
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Total assets | 5.83M | 5.27M | 49.13M | 22.28M | 31.53M |
| Total liabilities | 3.43M | 3.57M | 46.9M | 10.17M | 6.02M |
| Total equity | 2.4M | 1.7M | 2.23M | 12.11M | 25.5M |
| Cash & equivalents | 1.88M | 1.73M | 7.58M | 11.45M | 16.99M |
| Current assets | 3.13M | 2.35M | 9.6M | 13.68M | 18.77M |
| Current liabilities | 3.11M | 2.94M | 6.57M | 7.65M | 3.68M |
| Accounts payable | 1.13M | 1.72M | 1.07M | 1.62M | 1.76M |
| Receivables | 95K | 437K | 425K | 951K | 684K |
| Goodwill | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M |
| Long-term debt | — | — | 6.77M | — | — |
Cash Flow
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Operating cash flow | -7.02M | -15.84M | -20.41M | -20.98M | -23.49M |
| Investing cash flow | -37K | -365K | -19K | -47K | -22.74M |
| Financing cash flow | 7.21M | 6.26M | 16.56M | 19.58M | 61.59M |
| Change in cash | 155K | -9.94M | -3.87M | -1.44M | 15.36M |
| Net income | -14.08M | -44.54M | -21.67M | -24.58M | -122.55M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | DEF 14A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | DEFA14A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | ARS — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14C — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | PRE 14C — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | EFFECT — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | CORRESP — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-3/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | UPLOAD — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-3 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 10-K — Ernexa Therapeutics Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Ernexa Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Cherington Charles | View Filing | |
| form 4 | Form 4 — Cherington Charles | View Filing | |
| edgar index | CERT — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-1/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-A12B — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | EFFECT — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-1/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-1 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | DRS — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 4 — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Gurrola Sandra M | View Filing | |
| form 4 | Form 4 — Gurrola Sandra M | View Filing | |
| edgar index | 424B3 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | EFFECT — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | UPLOAD — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | CORRESP — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-3 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | S-8 — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Cherington Charles | View Filing | |
| edgar index | 8-K — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Ernexa Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Ernexa Therapeutics Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free